Benzinga
Benzinga
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Benzinga
samedi, octobre 17
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Novo Nordisk AS
NVO
NYSE
Liste de surveillance
Get Report
Trade with Public
Get Report
Trade with Public
$38.83
-0.39
-0.99%
Dern. MÀJ: Oct 16, 7:59 PM
$38.73
-0.49
-1.25%
Get Report
Aperçu
Actualités
Prévisions de résultats
Objectifs de cours
Données financières
Sentiment
Actionnariat
Comparer
Options
Rapport sur les stocks
Privacy Manager
Novo Nordisk Financials
Novo Nordisk (NVO) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
At Novo Nordisk Capital Markets Day, Co CFO Says Reasonable To Expect That We Should Be Able To Grow The Company By Mid-Single Digits Compound Annual Growth Rate Toward 2030
https://edge.media-server.com/mmc/p/xdjeyf7u/
Benzinga Newsdesk
Hims & Hers Health: Investments Necessary For Long-Term Incremental Growth, Says Bullish Analyst
HIMS stock edges lower after mixed Q2 results. Needham analyst maintains Buy rating, raises PT to $42. Company's revenue up 38.2% YoY.
Priya Nigam
PRO
Novo Nordisk Q2 Adj. EPS $0.96 Beats $0.81 Estimate, Sales $12.209B Beat $11.350B Estimate
Novo Nordisk (NYSE:NVO) reported quarterly earnings of $0.96 per share which beat the analyst consensus estimate of $0.81 by 18.52 percent. This is a 5.49 percent increase over earnings of $0.91 per share from the same
Benzinga Newsdesk
Ozempic Maker Novo Nordisk Raises Outlook but Sales Fall on Tough Comparison, Stock Tanks
Novo Nordisk raises 2026 guidance as Wegovy pill tops 5 million U.S. prescriptions, but stock falls despite higher GLP-1 sales expectations.
Vandana Singh
PRO
Novo Nordisk Expects Outlook FY Adjusted Revenue Growth -6 To 0%; Q2 Adj Sales Up 7% At CER; Adj Operating Profit Up 11% At CER; Raises 2026 Adj Sales, Operating Profit Outlook To 0% To -6% At Cer; Improved Outlook Is Driven By Increased Expectations For Glp-1 Product Sales
Novo Nordisk today announced adjusted sales and adjusted operating profit for the second quarter of 2026 and raised 2026 full-year adjusted sales and adjusted operating profit outlook at CER.
Benzinga Newsdesk
Earnings Volatility Watch: SanDisk and Nine Other Stocks Could Swing Up To 17.5% This Week
SanDisk, Western Digital and eight other names carry the biggest implied earnings moves in the first week of August, led by the memory chipmakers.
Piero Cingari
